MustGrow Announces Record Q3-2025 Results
Rhea-AI Summary
MustGrow (OTCQB: MGROF) reported Q3-2025 operating and financial results for the three months ended September 30, 2025, announcing its first recorded quarterly sales since the prior-year period.
- Sales revenue: $0.8 million in Q3-2025 vs. no revenue in Q3-2024
- Gross profit: $180,555; gross margin 22.9% (up from 20.9% in Q2-2025)
- Cash and equivalents: $3.3 million as of September 30, 2025
- Inventory: $1.9 million as of September 30, 2025
The company noted Q3 is a seasonal shoulder period for Canadian agriculture and expects stronger retail demand in Q4-2025 and Q1-2026 as farmers buy crop inputs. Management cited margin improvement driven by higher-margin product sales through NexusBioAg and continues to allocate capital toward NexusBioAg and U.S. TerraSante biofertility sales.
Positive
- Recorded $0.8M sales revenue in Q3-2025 (vs. $0 in Q3-2024)
- Gross profit of $180,555 with margin at 22.9% (up from 20.9% Q2-2025)
- Cash and equivalents of $3.3M on hand as of Sept 30, 2025
Negative
- Q3 revenue remained low at only $0.8M during a seasonal shoulder quarter
- Inventory of $1.9M ties up working capital as of Sept 30, 2025
Investor Webcast: Wednesday, November 26th at 4:00pm ET / 1:00pm PT.
Register/View Here: https://us02web.zoom.us/webinar/register/8617635107958/WN_Ka6aNlTZTLuCJPaetQoLuQ.
Please join/register at least 5 minutes prior to the call.
Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.
Saskatoon, Saskatchewan--(Newsfile Corp. - November 25, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended September 30, 2025. For complete details, please refer to the Q3-2025 Condensed Interim Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.
Key Financial Highlights:
- Sales revenue of
$0.8 million was recorded in Q3-2025 vs. no revenue in Q3-2024 - Gross profit of
$180,555 equating to a22.9% gross profit margin in Q3-2025 (up from20.9% in Q2-2025)(1) - Cash and equivalents on hand as at September 30, 2025 was
$3.3 million with inventory of$1.9 million
"The third calendar quarter is typically the lowest product revenue 'shoulder season' for Canadian agriculture as farmers are harvesting their crops rather than purchasing input products. MustGrow's gross profit margin improvement over the second quarter resulted from higher margin product sales through our Canadian sales and distribution division, NexusBioAg," stated Corey Giasson, President and CEO of MustGrow. "As mentioned in previous earnings calls, Q1 and Q4 are traditionally stronger sales periods, as Canadian farmers purchase crop inputs. We are looking forward to a strong finish to the year in Q4 and also Q1-2026 as farmers purchase products in preparation for the 2026 growing season."
The Company continues to focus on capital allocation that generates revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility product sales in the U.S.
Notes:
1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.
About MustGrow
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 58.9 million common shares issued and outstanding and 69.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
MustGrow's Forward-Looking Statements
Certain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
Neither the TSX Venture Exchange, nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2025 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275899
FAQ
What did MustGrow (MGROF) report for Q3-2025 revenue?
What was MustGrow's gross margin in Q3-2025 and how did it change from Q2-2025?
How much cash did MustGrow (MGROF) have at September 30, 2025?
Why is Q3 typically weaker for MustGrow's sales according to management?
What business areas is MustGrow prioritizing for revenue growth after Q3-2025?
